Christian Klemt Sells 1,796 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 1,796 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.55, for a total value of $13,559.80. Following the completion of the sale, the chief financial officer now owns 166,713 shares in the company, valued at $1,258,683.15. This represents a 1.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

uniQure Stock Up 109.6 %

Shares of NASDAQ:QURE traded up $8.00 during trading hours on Tuesday, reaching $15.30. The stock had a trading volume of 61,665,105 shares, compared to its average volume of 1,618,237. uniQure has a 1 year low of $3.73 and a 1 year high of $17.39. The firm’s 50 day moving average is $6.42 and its 200-day moving average is $6.15. The stock has a market capitalization of $745.72 million, a price-to-earnings ratio of -3.08 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Research analysts predict that uniQure will post -3.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. acquired a new position in uniQure in the third quarter valued at approximately $7,360,000. Geode Capital Management LLC lifted its position in shares of uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after buying an additional 6,362 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $283,000. Quarry LP acquired a new position in shares of uniQure in the 3rd quarter valued at $58,000. Finally, RTW Investments LP purchased a new position in shares of uniQure in the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on QURE shares. The Goldman Sachs Group cut their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada cut their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Tuesday. StockNews.com raised uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $20.00 to $52.00 in a report on Tuesday. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $27.33.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.